Fidelity Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.02M Sell
287,316
-2,378,933
-89% -$53.6M ﹤0.01% 2237
2025
Q4
$61.3M Sell
2,666,249
-4,617,047
-63% -$152M ﹤0.01% 1358
2025
Q3
$219M Buy
7,283,296
+4,678,708
+180% +$140M 0.01% 800
2025
Q2
$94.7M Buy
2,604,588
+2,223,166
+583% +$80.1M 0.01% 1141
2025
Q1
$13.8M Sell
381,422
-14,562
-4% -$606K ﹤0.01% 1801
2024
Q4
$16.7M Sell
395,984
-241,837
-38% -$12M ﹤0.01% 1788
2024
Q3
$35.4M Sell
637,821
-9,797
-2% -$499K ﹤0.01% 1511
2024
Q2
$26.6M Sell
647,618
-134,414
-17% -$5.74M ﹤0.01% 1548
2024
Q1
$36.5M Sell
782,032
-210,919
-21% -$9.95M ﹤0.01% 1439
2023
Q4
$47.5M Sell
992,951
-34,834
-3% -$1.35M ﹤0.01% 1312
2023
Q3
$36.6M Buy
1,027,785
+195,108
+23% +$7.73M ﹤0.01% 1361
2023
Q2
$38.4M Sell
832,677
-171,347
-17% -$7.95M ﹤0.01% 1375
2023
Q1
$40.3M Sell
1,004,024
-75,050
-7% -$3.22M ﹤0.01% 1338
2022
Q4
$50M Buy
1,079,074
+99,295
+10% +$3.91M 0.01% 1253
2022
Q3
$40.6M Sell
979,779
-178,463
-15% -$9.17M ﹤0.01% 1329
2022
Q2
$69.1M Sell
1,158,242
-97,282
-8% -$5.99M 0.01% 1119
2022
Q1
$91.2M Sell
1,255,524
-35,855
-3% -$2.49M 0.01% 1105
2021
Q4
$109M Buy
1,291,379
+130,394
+11% +$10.6M 0.01% 1067
2021
Q3
$105M Buy
1,160,985
+286,371
+33% +$25.9M 0.01% 1086
2021
Q2
$83.4M Sell
874,614
-2,900
-0.3% -$302K 0.01% 1200
2021
Q1
$99.9M Sell
877,514
-193,985
-18% -$26.4M 0.01% 1066
2020
Q4
$148M Sell
1,071,499
-98,600
-8% -$11.7M 0.01% 868
2020
Q3
$96.2M Sell
1,170,099
-272,003
-19% -$22.5M 0.01% 923
2020
Q2
$113M Sell
1,442,102
-333,608
-19% -$22.1M 0.01% 828
2020
Q1
$78.9M Sell
1,775,710
-47,664
-3% -$2.47M 0.01% 847
2019
Q4
$77.9M Sell
1,823,374
-260,247
-12% -$10.7M 0.01% 1018
2019
Q3
$89.1M Sell
2,083,621
-207,667
-9% -$11.3M 0.01% 934
2019
Q2
$145M Sell
2,291,288
-226,458
-9% -$14.4M 0.02% 769
2019
Q1
$175M Sell
2,517,746
-429,178
-15% -$24.5M 0.02% 698
2018
Q4
$128M Sell
2,946,924
-380,457
-11% -$20.8M 0.02% 742
2018
Q3
$254M Sell
3,327,381
-131,704
-4% -$10.7M 0.03% 583
2018
Q2
$266M Sell
3,459,085
-485,897
-12% -$31.4M 0.03% 553
2018
Q1
$201M Buy
3,944,982
+303,061
+8% +$15.3M 0.02% 681
2017
Q4
$169M Sell
3,641,921
-15,287
-0.4% -$750K 0.02% 761
2017
Q3
$195M Sell
3,657,208
-147,017
-4% -$8.71M 0.02% 694
2017
Q2
$236M Sell
3,804,225
-2,306,402
-38% -$139M 0.03% 615
2017
Q1
$414M Buy
6,110,627
+227,802
+4% +$17.4M 0.05% 389
2016
Q4
$414M Sell
5,882,825
-30,250
-0.5% -$2.15M 0.06% 370
2016
Q3
$419M Buy
5,913,075
+65,292
+1% +$4.17M 0.06% 373
2016
Q2
$286M Buy
5,847,783
+6,152
+0.1% +$398K 0.04% 519
2016
Q1
$370M Buy
5,841,631
+18,689
+0.3% +$1.22M 0.05% 389
2015
Q4
$653M Buy
5,822,942
+22,946
+0.4% +$2.29M 0.09% 232
2015
Q3
$559M Buy
5,799,996
+419,169
+8% +$48M 0.08% 268
2015
Q2
$551M Buy
5,380,827
+48,044
+0.9% +$3.73M 0.07% 309
2015
Q1
$331M Buy
5,332,783
+551,363
+12% +$30.6M 0.04% 474
2014
Q4
$210M Buy
4,781,420
+187,180
+4% +$8.58M 0.03% 653
2014
Q3
$260M Buy
4,594,240
+85,347
+2% +$4.29M 0.04% 533
2014
Q2
$125M Buy
4,508,893
+908,405
+25% +$37.4M 0.02% 881
2014
Q1
$85.1M Buy
+3,600,488
New +$185M 0.01% 1068

Other funds holding RARE

Fidelity Investments's RARE Position: Q1 2026 in Review

Fidelity Investments reduced its Ultragenyx Pharmaceutical (RARE) stake by 89% in Q1 2026, selling an estimated $53.6M and leaving 287,316 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Fidelity Investments first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $653M in Q4 2015. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Fidelity Investments held 287,316 shares of Ultragenyx Pharmaceutical worth $6.02M as of Q1 2026.
  • Fidelity Investments sold 2,378,933 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $53.6M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2237 holding.
  • Fidelity Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Fidelity Investments's Ultragenyx Pharmaceutical position peaked at $653M in Q4 2015.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.